Drug Trial Radar · NCT00089791
A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis
Last checked: Nov 20, 2026Latest source record: Nov 8, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,808
Actual
Start
Aug 1, 2004
Primary completion
Jun 17, 2008
Study completion Jun 17, 2008
Sponsor
- Lead sponsor
- AmgenAmgen (AMGN)
- Sponsor type
- Industry
- First posted
- Aug 16, 2004
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- Female only, from 60 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the effectiveness and safety of denosumab in treating women with Postmenopausal Osteoporosis.
Conditions
- Osteoporosis
Interventions
placeboDrug
Placebo administered by subcutaneous injection
DenosumabDrug
Denosumab 60 mg administered by subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With New Vertebral FracturesTime frame: 36 months
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.